A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia.
Therapeutic and adverse effects of three dosages (1, 20 and 100 mg daily) of flutroline, a new gamma-carboline with a preclinical pharmacological profile similar to active neuroleptic agents, were compared in a double-blind clinical trial in 25 newly-admitted schizophrenic patients. Therapeutic effects and extrapyramidal signs were seen at the 20 and 100-mg daily dosages, but not at the 1-mg dosage. Serum prolactin levels were significantly elevated only at the 100-mg daily dosage.